Compare BKE & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKE | ADPT |
|---|---|---|
| Founded | 1948 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.7B |
| IPO Year | 1996 | 2019 |
| Metric | BKE | ADPT |
|---|---|---|
| Price | $41.95 | $21.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $53.00 | $17.78 |
| AVG Volume (30 Days) | 491.0K | ★ 4.0M |
| Earning Date | 05-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 7.96% | N/A |
| EPS Growth | 6.43 | ★ 63.89 |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $1,297,835,000.00 | $276,976,000.00 |
| Revenue This Year | $5.10 | $3.98 |
| Revenue Next Year | $4.99 | $22.72 |
| P/E Ratio | $45.86 | ★ N/A |
| Revenue Growth | 6.58 | ★ 54.77 |
| 52 Week Low | $40.93 | $9.96 |
| 52 Week High | $61.69 | $22.80 |
| Indicator | BKE | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 36.45 | 66.83 |
| Support Level | N/A | $15.08 |
| Resistance Level | $45.81 | N/A |
| Average True Range (ATR) | 1.34 | 1.27 |
| MACD | -0.00 | 0.33 |
| Stochastic Oscillator | 25.56 | 76.67 |
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.